EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast

Semir Vranic, Ossama Tawfik, Juan Palazzo, Nurija Bilalovic, Eduardo Eyzaguirre, Lisa Mj Lee, Patrick Adegboyega, Jill Hagenkord, Zoran Gatalica

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

This study was undertaken to investigate epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2)/neu expression in a cohort of apocrine carcinomas of the breast with emphasis on the classification of the breast tumors with apocrine morphology. In total, 55 breast carcinomas morphologically diagnosed as apocrine were evaluated for the steroid receptor expression profile characteristic of normal apocrine epithelium (androgen receptor positive/estrogen receptor (ER) negative/progesterone receptor (PR) negative), and for the expression of EGFR and Her-2/neu proteins, and the copy number ratios of the genes EGFR/CEP7 and HER-2/CEP17. On the basis of the results of steroid receptors expression, 38 (69%) cases were classified as pure apocrine carcinoma (androgen receptor positive/ER negative/PR negative), whereas 17 (31%) were re-classified as apocrine-like carcinomas because they did not have the characteristic steroid receptor expression profile. Her-2/neu overexpression was observed in 54% of the cases (57% pure apocrine carcinomas vs 47% apocrine-like carcinomas). HER-2/neu gene amplification was demonstrated in 52% of all cases (54% pure apocrine carcinomas vs 46% apocrine-like carcinomas). EGFR protein (scores 1 to 3) was detected in 62% of all cases and was expressed in a higher proportion of pure apocrine carcinomas than in the apocrine-like carcinomas group (76 vs 29%, P0.006). In the pure apocrine carcinoma group, Her-2/neu and EGFR protein expression were inversely correlated (P0.006, r0.499). EGFR gene amplification was observed in two pure apocrine carcinomas and one apocrine-like carcinoma. Polysomy 7 was commonly present in pure apocrine carcinomas (61 vs 27% of apocrine-like carcinomas; P0.083) and showed a weak positive correlation with EGFR protein expression (P0.025, r0.326). Our study showed that apocrine breast carcinomas are molecularly diverse group of carcinomas. Strictly defined pure apocrine carcinomas are either HER-2-overexpressing breast carcinomas or triple-negative breast carcinomas, whereas apocrine-like carcinomas predominantly belong to the luminal phenotype. Pure apocrine carcinomas show consistent overexpression of either EGFR or HER-2/neu, which could have significant therapeutic implications.

Original languageEnglish (US)
Pages (from-to)644-653
Number of pages10
JournalModern Pathology
Volume23
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Epidermal Growth Factor Receptor
Breast Neoplasms
Carcinoma
Steroid Receptors
erbB-1 Genes
human ERBB2 protein
Gene Amplification
Androgen Receptors
Progesterone Receptors
Estrogen Receptors
Proteins
erbB-2 Genes

Keywords

  • Apocrine carcinoma
  • Breast
  • Gene amplification
  • HER-1/EGFR
  • HER-2/neu
  • Polysomy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Vranic, S., Tawfik, O., Palazzo, J., Bilalovic, N., Eyzaguirre, E., Lee, L. M., ... Gatalica, Z. (2010). EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Modern Pathology, 23(5), 644-653. https://doi.org/10.1038/modpathol.2010.50

EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. / Vranic, Semir; Tawfik, Ossama; Palazzo, Juan; Bilalovic, Nurija; Eyzaguirre, Eduardo; Lee, Lisa Mj; Adegboyega, Patrick; Hagenkord, Jill; Gatalica, Zoran.

In: Modern Pathology, Vol. 23, No. 5, 05.2010, p. 644-653.

Research output: Contribution to journalArticle

Vranic, S, Tawfik, O, Palazzo, J, Bilalovic, N, Eyzaguirre, E, Lee, LM, Adegboyega, P, Hagenkord, J & Gatalica, Z 2010, 'EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast', Modern Pathology, vol. 23, no. 5, pp. 644-653. https://doi.org/10.1038/modpathol.2010.50
Vranic, Semir ; Tawfik, Ossama ; Palazzo, Juan ; Bilalovic, Nurija ; Eyzaguirre, Eduardo ; Lee, Lisa Mj ; Adegboyega, Patrick ; Hagenkord, Jill ; Gatalica, Zoran. / EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. In: Modern Pathology. 2010 ; Vol. 23, No. 5. pp. 644-653.
@article{9a4b21c993824ff1bb451b3e084ca755,
title = "EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast",
abstract = "This study was undertaken to investigate epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2)/neu expression in a cohort of apocrine carcinomas of the breast with emphasis on the classification of the breast tumors with apocrine morphology. In total, 55 breast carcinomas morphologically diagnosed as apocrine were evaluated for the steroid receptor expression profile characteristic of normal apocrine epithelium (androgen receptor positive/estrogen receptor (ER) negative/progesterone receptor (PR) negative), and for the expression of EGFR and Her-2/neu proteins, and the copy number ratios of the genes EGFR/CEP7 and HER-2/CEP17. On the basis of the results of steroid receptors expression, 38 (69{\%}) cases were classified as pure apocrine carcinoma (androgen receptor positive/ER negative/PR negative), whereas 17 (31{\%}) were re-classified as apocrine-like carcinomas because they did not have the characteristic steroid receptor expression profile. Her-2/neu overexpression was observed in 54{\%} of the cases (57{\%} pure apocrine carcinomas vs 47{\%} apocrine-like carcinomas). HER-2/neu gene amplification was demonstrated in 52{\%} of all cases (54{\%} pure apocrine carcinomas vs 46{\%} apocrine-like carcinomas). EGFR protein (scores 1 to 3) was detected in 62{\%} of all cases and was expressed in a higher proportion of pure apocrine carcinomas than in the apocrine-like carcinomas group (76 vs 29{\%}, P0.006). In the pure apocrine carcinoma group, Her-2/neu and EGFR protein expression were inversely correlated (P0.006, r0.499). EGFR gene amplification was observed in two pure apocrine carcinomas and one apocrine-like carcinoma. Polysomy 7 was commonly present in pure apocrine carcinomas (61 vs 27{\%} of apocrine-like carcinomas; P0.083) and showed a weak positive correlation with EGFR protein expression (P0.025, r0.326). Our study showed that apocrine breast carcinomas are molecularly diverse group of carcinomas. Strictly defined pure apocrine carcinomas are either HER-2-overexpressing breast carcinomas or triple-negative breast carcinomas, whereas apocrine-like carcinomas predominantly belong to the luminal phenotype. Pure apocrine carcinomas show consistent overexpression of either EGFR or HER-2/neu, which could have significant therapeutic implications.",
keywords = "Apocrine carcinoma, Breast, Gene amplification, HER-1/EGFR, HER-2/neu, Polysomy",
author = "Semir Vranic and Ossama Tawfik and Juan Palazzo and Nurija Bilalovic and Eduardo Eyzaguirre and Lee, {Lisa Mj} and Patrick Adegboyega and Jill Hagenkord and Zoran Gatalica",
year = "2010",
month = "5",
doi = "10.1038/modpathol.2010.50",
language = "English (US)",
volume = "23",
pages = "644--653",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast

AU - Vranic, Semir

AU - Tawfik, Ossama

AU - Palazzo, Juan

AU - Bilalovic, Nurija

AU - Eyzaguirre, Eduardo

AU - Lee, Lisa Mj

AU - Adegboyega, Patrick

AU - Hagenkord, Jill

AU - Gatalica, Zoran

PY - 2010/5

Y1 - 2010/5

N2 - This study was undertaken to investigate epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2)/neu expression in a cohort of apocrine carcinomas of the breast with emphasis on the classification of the breast tumors with apocrine morphology. In total, 55 breast carcinomas morphologically diagnosed as apocrine were evaluated for the steroid receptor expression profile characteristic of normal apocrine epithelium (androgen receptor positive/estrogen receptor (ER) negative/progesterone receptor (PR) negative), and for the expression of EGFR and Her-2/neu proteins, and the copy number ratios of the genes EGFR/CEP7 and HER-2/CEP17. On the basis of the results of steroid receptors expression, 38 (69%) cases were classified as pure apocrine carcinoma (androgen receptor positive/ER negative/PR negative), whereas 17 (31%) were re-classified as apocrine-like carcinomas because they did not have the characteristic steroid receptor expression profile. Her-2/neu overexpression was observed in 54% of the cases (57% pure apocrine carcinomas vs 47% apocrine-like carcinomas). HER-2/neu gene amplification was demonstrated in 52% of all cases (54% pure apocrine carcinomas vs 46% apocrine-like carcinomas). EGFR protein (scores 1 to 3) was detected in 62% of all cases and was expressed in a higher proportion of pure apocrine carcinomas than in the apocrine-like carcinomas group (76 vs 29%, P0.006). In the pure apocrine carcinoma group, Her-2/neu and EGFR protein expression were inversely correlated (P0.006, r0.499). EGFR gene amplification was observed in two pure apocrine carcinomas and one apocrine-like carcinoma. Polysomy 7 was commonly present in pure apocrine carcinomas (61 vs 27% of apocrine-like carcinomas; P0.083) and showed a weak positive correlation with EGFR protein expression (P0.025, r0.326). Our study showed that apocrine breast carcinomas are molecularly diverse group of carcinomas. Strictly defined pure apocrine carcinomas are either HER-2-overexpressing breast carcinomas or triple-negative breast carcinomas, whereas apocrine-like carcinomas predominantly belong to the luminal phenotype. Pure apocrine carcinomas show consistent overexpression of either EGFR or HER-2/neu, which could have significant therapeutic implications.

AB - This study was undertaken to investigate epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2)/neu expression in a cohort of apocrine carcinomas of the breast with emphasis on the classification of the breast tumors with apocrine morphology. In total, 55 breast carcinomas morphologically diagnosed as apocrine were evaluated for the steroid receptor expression profile characteristic of normal apocrine epithelium (androgen receptor positive/estrogen receptor (ER) negative/progesterone receptor (PR) negative), and for the expression of EGFR and Her-2/neu proteins, and the copy number ratios of the genes EGFR/CEP7 and HER-2/CEP17. On the basis of the results of steroid receptors expression, 38 (69%) cases were classified as pure apocrine carcinoma (androgen receptor positive/ER negative/PR negative), whereas 17 (31%) were re-classified as apocrine-like carcinomas because they did not have the characteristic steroid receptor expression profile. Her-2/neu overexpression was observed in 54% of the cases (57% pure apocrine carcinomas vs 47% apocrine-like carcinomas). HER-2/neu gene amplification was demonstrated in 52% of all cases (54% pure apocrine carcinomas vs 46% apocrine-like carcinomas). EGFR protein (scores 1 to 3) was detected in 62% of all cases and was expressed in a higher proportion of pure apocrine carcinomas than in the apocrine-like carcinomas group (76 vs 29%, P0.006). In the pure apocrine carcinoma group, Her-2/neu and EGFR protein expression were inversely correlated (P0.006, r0.499). EGFR gene amplification was observed in two pure apocrine carcinomas and one apocrine-like carcinoma. Polysomy 7 was commonly present in pure apocrine carcinomas (61 vs 27% of apocrine-like carcinomas; P0.083) and showed a weak positive correlation with EGFR protein expression (P0.025, r0.326). Our study showed that apocrine breast carcinomas are molecularly diverse group of carcinomas. Strictly defined pure apocrine carcinomas are either HER-2-overexpressing breast carcinomas or triple-negative breast carcinomas, whereas apocrine-like carcinomas predominantly belong to the luminal phenotype. Pure apocrine carcinomas show consistent overexpression of either EGFR or HER-2/neu, which could have significant therapeutic implications.

KW - Apocrine carcinoma

KW - Breast

KW - Gene amplification

KW - HER-1/EGFR

KW - HER-2/neu

KW - Polysomy

UR - http://www.scopus.com/inward/record.url?scp=77952009500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952009500&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2010.50

DO - 10.1038/modpathol.2010.50

M3 - Article

VL - 23

SP - 644

EP - 653

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 5

ER -